Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Sees Significantly Higher Trading Volume

Cornelia Mascio
Luglio 17, 2017

Zimmer Biomet Holdings, Inc. had its " rating reiterated by analysts at Bank of America Merrill Lynch. (NYSE:ZBH) by 12.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The analysts, on average, are forecasting a $135 price target, but the stock is already up 38.54% from its recent lows.

Several other hedge funds have also modified their holdings of the stock. Levin Capital Strategies L.P. raised its stake in shares of Zimmer Biomet Holdings by 41.9% in the fourth quarter. During the same quarter past year, the business posted $2.00 EPS. Cleararc Capital Inc. now owns 4,897 shares of the medical equipment provider's stock worth $598,000 after buying an additional 25 shares during the period. Zimmer Biomet Holdings Inc (NYSE:ZBH) has declined 0.44% since July 17, 2016 and is downtrending. The latest reports which are outstanding on Monday 17th of July state 10 analysts have a rating of "strong buy", 8 analysts "buy", 8 analysts "neutral", 1 analysts "sell" and 1 analysts "strong sell". Thrivent Financial for Lutherans raised its stake in shares of Zimmer Biomet Holdings by 6.7% in the fourth quarter. Insiders own 1.07% of the company's stock.

OppenheimerFunds Inc. cut its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) traded at an unexpectedly high level on 07/14/2017 when the stock experienced a 2.72% gain to a closing price of $132.49.

Company shares last traded at $132.49 which is a tad above $123.43, the 50 day moving average and a tad above the 200 day moving average of $117.75.

07/12/2017 - Zimmer Biomet Holdings, Inc. had its " rating reiterated by analysts at RBC Capital. If the $143.99 price target is reached, the company will be worth $2.46 billion more. Cim Investment Mangement Inc. now owns 6,456 shares of the medical equipment provider's stock valued at $666,000 after buying an additional 76 shares during the period. The business had revenue of $1.98 billion during the quarter, compared to the consensus estimate of $1.96 billion. Zimmer Biomet Holdings had a net margin of 6.36% and a return on equity of 16.80%. Zimmer Biomet Holdings's quarterly revenue was up 3.8% compared to the same quarter past year. During the same period in the prior year, the business posted $2.00 earnings per share. Currently, Zimmer Biomet Holdings has an average volume of 603.5K.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 28th. Stockholders of record on Friday, June 23rd will be issued a dividend of $0.24 per share. The ex-dividend date is Wednesday, June 21st. This represents a $0.96 dividend on an annualized basis and a yield of 0.72%. Zimmer Biomet Holdings's dividend payout ratio is presently 39.67%.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Markets Daily and is owned by of Markets Daily. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and worldwide copyright & trademark law. The legal version of this piece can be accessed at https://www.themarketsdaily.com/2017/07/17/zimmer-biomet-holdings-inc-zbh-shares-bought-by-fil-ltd-updated-updated.html. Stifel Nicolaus reaffirmed a "hold" rating and issued a $125.00 target price on shares of Zimmer Biomet Holdings in a research report on Friday. On July 12 the company was upgraded from " to "Buy" in a report issued by Guggenheim. Creative Planning now owns 15,334 shares of the medical equipment provider's stock worth $1,872,000 after buying an additional 3,184 shares during the last quarter. Canaccord Genuity reissued a "buy" rating and set a $141.00 price target on shares of Zimmer Biomet Holdings in a research report on Friday. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $140.00 target price on shares of Zimmer Biomet Holdings in a research report on Friday. The company now has an average rating of "Buy" and a consensus price target of $137.19. The sale was disclosed in a filing with the SEC, which is available through this link.

In related news, insider David C. Dvorak sold 87,331 shares of the company's stock in a transaction on Thursday, April 27th. The shares were sold on April 27th for an average price of $116.56. Following the sale, the insider now directly owns 381,886 shares of the company's stock, valued at approximately $44,478,262.42. In the last ninety days, insiders sold 111,262 shares of company stock worth $13,103,927.

Zimmer Biomet Holdings, Inc.is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE